Evidence map›Paper›PMID 41419472›Full record

ArticleNature communications2025

Thrombopoietin increases susceptibility for EVI1 + KMT2A-MLLT3-driven AML expressing stem cell genes linked to poor outcome.

Hugues-Étienne Châtel-Soulet, Sabine Juge, Ana Luisa Pereira, Jonathan Seguin, Athimed El Taher, Federica Valigi, Zivojin Jevtic, Rathick Sivalingam, Frederik Otzen Bagger, Paul Büschl and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Hugues-Étienne Châtel-Soulet *University Children's Hospital & Department of Biomedicine, University of Basel, Basel, Switzerland.
Sabine Juge *University Children's Hospital & Department of Biomedicine, University of Basel, Basel, Switzerland.
Ana Luisa PereiraDepartment of Medical Oncology and Haematology, University Hospital Zürich, Zürich, Switzerland.
Jonathan SeguinUniversity Children's Hospital & Department of Biomedicine, University of Basel, Basel, Switzerland.ORCID http://orcid.org/0000-0002-3676-0437
Athimed El TaherSwiss Institute of Bioinformatics (SIB), Basel, Switzerland.ORCID http://orcid.org/0000-0003-2424-8476
Federica ValigiUniversity Children's Hospital & Department of Biomedicine, University of Basel, Basel, Switzerland.ORCID http://orcid.org/0009-0006-8241-1605
Zivojin JevticUniversity Children's Hospital & Department of Biomedicine, University of Basel, Basel, Switzerland.
Rathick SivalingamUniversity Children's Hospital & Department of Biomedicine, University of Basel, Basel, Switzerland.
Frederik Otzen BaggerUniversity Children's Hospital & Department of Biomedicine, University of Basel, Basel, Switzerland.ORCID http://orcid.org/0000-0003-0636-8845
Paul BüschlDepartment of Medical Oncology and Haematology, University Hospital Zürich, Zürich, Switzerland.ORCID http://orcid.org/0009-0002-6685-241X
Marwa AlmosailleakhUniversity Children's Hospital & Department of Biomedicine, University of Basel, Basel, Switzerland.
Alexander TzankovInstitute for Pathology, University of Basel, Basel, Switzerland.ORCID http://orcid.org/0000-0002-1100-3819
Wei TongDivision of Haematology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0001-9951-2273
Mineo KurokawaDepartment of Haematology and Oncology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
César Nombela ArrietaDepartment of Medical Oncology and Haematology, University Hospital Zürich, Zürich, Switzerland.ORCID http://orcid.org/0000-0003-0415-259X
Juerg SchwallerUniversity Children's Hospital & Department of Biomedicine, University of Basel, Basel, Switzerland. J.Schwaller@unibas.ch.ORCID http://orcid.org/0000-0001-8616-0096

Funding

Regulation of Ribosome Biogenesis in Hematopoietic Stem CellsR01DK127738 · NIDDK · CHILDREN'S HOSP OF PHILADELPHIA · PI TONG, WEI · 2020 to 2024
$3.0M
Novel Regulation of Oncogenic NRAS Signaling in Myeloid MalignanciesR01CA271523 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI Wei Tong · 2022 to 2026
$2.7M
Regulation of FLT3 Signaling in LeukemiaR01CA282668 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI Wei Tong · 2023 to 2026
$2.5M
Regulation of protein ubiquitination in hematopoietic cytokine signalingR01HL133828 · NHLBI · CHILDREN'S HOSP OF PHILADELPHIA · PI TONG, WEI · 2017 to 2020
$2.2M
NCI NIH HHS R01 CA271523NCI NIH HHS R01 CA282668NHLBI NIH HHS R01 HL133828NIDDK NIH HHS R01 DK127738Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation) 31003A_173224/1
6 · The paper itself

Abstract

To address the cellular origin of ecotropic virus integration site 1 (EVI1)-expressing aggressive KMT2A-rearranged acute myeloid leukaemia (AML) we integrate an Evi1-GFP reporter allele in the inducible iKMT2A-MLLT3 mouse model. We observe that a single injection of thrombopoietin (TPO) selectively increases the number of cycling Evi1

Indexed as

Histone-Lysine N-MethyltransferaseLeukemia, Myeloid, AcuteMDS1 and EVI1 Complex Locus ProteinMyeloid-Lymphoid Leukemia ProteinThrombopoietinAnimalsDisease Models, AnimalHematopoietic Stem CellsHL-60 CellsHumansMiceOncogene Proteins, FusionHistone-Lysine N-MethyltransferaseKMT2A protein, humanMDS1 and EVI1 Complex Locus ProteinMECOM protein, humanMecom protein, mouseMyeloid-Lymphoid Leukemia ProteinOncogene Proteins, FusionThrombopoietin

Identifiers

PMID41419472
PMCPMC12830621

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.